Effects of combined radiotherapy with immune checkpoint blockade on immunological memory in luminal-like subtype murine bladder cancer model

References

• Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–9. doi:10.3322/caac.21708.
   PubMed Web of Science ®Google Scholar
• Felsenstein KM, Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nat Rev Urol. 2018;15(2):92–111. doi:10.1038/nrurol.2017.179.
   PubMed Web of Science ®Google Scholar
• Hayes J, Chhaya S, Manning H, Ng K, Sharma A, Vasdev N. Management of MIBC. In: Singh P, Nayak B, Panaiyadiyan S. editors. A guide to management of urological cancers. Singapore: Springer Nature Singapore; 2023. p. 153–67.
   Google Scholar
• Giridhar KV, Kohli M. Management of muscle-invasive urothelial cancer and the emerging role of immunotherapy in advanced urothelial cancer. Mayo Clin Proc. 2017;92(10):1564–82. doi:10.1016/j.mayocp.2017.07.010.
   PubMed Web of Science ®Google Scholar
• Burdett S, Fisher DJ, Vale CL, Sternberg CN, Clarke NW, Parmar MKB, Bono AV, Cognetti F, Collette L, Cote RJ. Advanced bladder cancer meta-analysis collaborators G: adjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and meta-analysis of individual participant data from randomised controlled trials. Eur Urol. 2022;81(1):50–61. doi:10.1016/j.eururo.2021.09.028.
   PubMed Web of Science ®Google Scholar
• Nadal R, Bellmunt J. Management of metastatic bladder cancer. Cancer Treat Rev. 2019;76:10–21. doi:10.1016/j.ctrv.2019.04.002.
   PubMed Web of Science ®Google Scholar
• Kamoun A, de Reyniès A, Allory Y, Sjödahl G, Robertson AG, Seiler R, Hoadley KA, Groeneveld CS, Al-Ahmadie H, Choi W, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420–33. doi:10.1016/j.eururo.2019.09.006.
   PubMed Web of Science ®Google Scholar
• Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, Roth B, Cheng T, Tran M, Lee IL, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25(2):152–65. doi:10.1016/j.ccr.2014.01.009.
   PubMed Web of Science ®Google Scholar
• Kim J, Kwiatkowski D, McConkey DJ, Meeks JJ, Freeman SS, Bellmunt J, Getz G, Lerner SP. The cancer genome atlas expression subtypes stratify response to checkpoint inhibition in advanced urothelial cancer and identify a subset of patients with high survival probability. European Urology. 2019;75(6):961–64. doi:10.1016/j.eururo.2019.02.017.
   PubMed Web of Science ®Google Scholar
• Silina L, Maksut F, Bernard-Pierrot I, Radvanyi F, Créhange G, Mégnin-Chanet F, Verrelle P. Review of experimental studies to improve radiotherapy response in bladder cancer: comments and perspectives. Cancers (Basel). 2020;13(1):87. doi:10.3390/cancers13010087.
   PubMed Web of Science ®Google Scholar
• Saito R, Smith CC, Utsumi T, Bixby LM, Kardos J, Wobker SE, Stewart KG, Chai S, Manocha U, Byrd KM, et al. Molecular subtype-specific immunocompetent models of high-grade urothelial carcinoma reveal differential neoantigen expression and response to immunotherapy. Cancer Res. 2018;78(14):3954–68. doi:10.1158/0008-5472.CAN-18-0173.
   PubMed Web of Science ®Google Scholar
• Yard BD, Adams DJ, Chie EK, Tamayo P, Battaglia JS, Gopal P, Rogacki K, Pearson BE, Phillips J, Raymond DP, et al. A genetic basis for the variation in the vulnerability of cancer to DNA damage. Nat Commun. 2016;7(1):11428. doi:10.1038/ncomms11428.
   PubMedGoogle Scholar
• Zuiverloon TCM, de Jong FC, Costello JC. Theodorescu D: systematic review: characteristics and preclinical uses of bladder cancer cell lines. Bladder Cancer. 2018;4(2):169–83. doi:10.3233/BLC-180167.
   PubMed Web of Science ®Google Scholar
• Wu CT, Chen WC, Chang YH, Lin WY, Chen MF. The role of PD-L1 in the radiation response and clinical outcome for bladder cancer. Sci Rep. 2016;6(1):19740. doi:10.1038/srep19740.
   PubMedGoogle Scholar
• Chamie K, Litwin MS, Bassett JC, Daskivich TJ, Lai J, Hanley JM, Konety BR, Saigal CS. Recurrence of high-risk bladder cancer: a population-based analysis. Cancer. 2013;119(17):3219–27. doi:10.1002/cncr.28147.
   PubMed Web of Science ®Google Scholar
• Demaria O, Cornen S, Daëron M, Morel Y, Medzhitov R, Vivier E. Harnessing innate immunity in cancer therapy. Nature. 2019;574(7776):45–56. doi:10.1038/s41586-019-1593-5.
   PubMed Web of Science ®Google Scholar
• Liu Q, Sun Z, Chen L. Memory T cells: strategies for optimizing tumor immunotherapy. Protein Cell. 2020;11(8):549–64. doi:10.1007/s13238-020-00707-9.
   PubMed Web of Science ®Google Scholar
• Bonaventura P, Shekarian T, Alcazer V, Valladeau-Guilemond J, Valsesia-Wittmann S, Amigorena S, Caux C, Depil S. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10(168). doi:10.3389/fimmu.2019.00168.
   PubMedGoogle Scholar
• Lhuillier C, Rudqvist NP, Elemento O, Formenti SC, Demaria S. Radiation therapy and anti-tumor immunity: exposing immunogenic mutations to the immune system. Genome Med. 2019;11(1):40. doi:10.1186/s13073-019-0653-7.
   PubMed Web of Science ®Google Scholar
• Singh P, Tangen C, Efstathiou JA, Lerner SP, Jhavar SG, Hahn NM, Costello BA, Sridhar SS, Du W, Meeks JJ, et al. INTACT: phase III randomized trial of concurrent chemoradiotherapy with or without atezolizumab in localized muscle invasive bladder cancer—SWOG/NRG1806. J Clin Oncol. 2020;38(6_suppl):TPS586–586. doi:10.1200/JCO.2020.38.6_suppl.TPS586.
   Web of Science ®Google Scholar
• Kassouf W, Crabb SJ, Duran I, Brundage MD, Reaume MN, Dragomir A, Wyatt AW, Badillo FEV, Lukka H, Niazi T, et al. CCTG BL13 a randomized phase II trial assessing trimodality therapy with or without adjuvant durvalumab to treat patients with muscle-invasive bladder cancer (NCT03768570). J Clin Oncol. 2022;40(16_suppl):TPS4619–4619. doi:10.1200/JCO.2022.40.16_suppl.TPS4619.
   Web of Science ®Google Scholar
• Daniels MA, Teixeiro E. TCR signaling in T cell memory. Front Immunol. 2015;6:617. doi:10.3389/fimmu.2015.00617.
   PubMed Web of Science ®Google Scholar
• Barnaba V. T cell memory in infection, cancer, and autoimmunity. Front Immunol. 2021;12:811968. doi:10.3389/fimmu.2021.811968.
   PubMed Web of Science ®Google Scholar
• Sckisel GD, Bouchlaka MN, Monjazeb AM, Crittenden M, Curti BD, Wilkins DE, Alderson KA, Sungur CM, Ames E, Mirsoian A, et al. Out-of-sequence signal 3 paralyzes primary CD4(+) T-Cell-dependent immunity. Immunity. 2015;43(2):240–50. doi:10.1016/j.immuni.2015.06.023.
   PubMed Web of Science ®Google Scholar
• Rompre-Brodeur A, Shinde-Jadhav S, Ayoub M, Piccirillo CA, Seuntjens J, Brimo F, Mansure JJ, Kassouf W. PD-1/PD-L1 immune checkpoint inhibition with radiation in bladder cancer: in situ and abscopal effects. Mol Cancer Ther. 2020;19(1):211–20. doi:10.1158/1535-7163.MCT-18-0986.
   PubMed Web of Science ®Google Scholar
• Martin MD, Badovinac VP. Defining memory CD8 T cell. Front Immunol. 2018;9(2692). doi:10.3389/fimmu.2018.02692.
   Google Scholar
• Gasper DJ, Tejera MM, Suresh M. CD4 T-cell memory generation and maintenance. Crit Rev Immunol. 2014;34(2):121–46. doi:10.1615/CritRevImmunol.2014010373.
   PubMed Web of Science ®Google Scholar
• Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization and homeostasis. Nat Rev Immunol. 2014;14(1):24–35. doi:10.1038/nri3567.
   PubMed Web of Science ®Google Scholar
• Woodland DL, Kohlmeier JE. Migration, maintenance and recall of memory T cells in peripheral tissues. Nat Rev Immunol. 2009;9(3):153–61. doi:10.1038/nri2496.
   PubMed Web of Science ®Google Scholar
• Yang S, Liu F, Wang QJ, Rosenberg SA, Morgan RA, Teague RM. The shedding of CD62L (L-selectin) regulates the acquisition of lytic activity in human tumor reactive T lymphocytes. PLOS ONE. 2011;6(7):e22560. doi:10.1371/journal.pone.0022560.
   PubMed Web of Science ®Google Scholar
• Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, et al. Discovering dominant tumor immune archetypes in a pan-cancer census. Cell. 2022;185(1):184–203.e19. doi:10.1016/j.cell.2021.12.004.
   PubMed Web of Science ®Google Scholar
• Liu S, Chen H, Zheng Z, He Y, Yao X. Development of a molecular-subtype-associated immune prognostic signature that can be recognized by MRI radiomics features in bladder cancer. Bioeng (Basel). 2023;10(3):318. doi:10.3390/bioengineering10030318.
   PubMedGoogle Scholar
• Benitez R, Yu K, Sirota M, Malats N, Pineda S. Characterization of the tumor-infiltrating immune repertoire in muscle invasive bladder cancer. Front Immunol. 2023;14:986598. doi:10.3389/fimmu.2023.986598.
   PubMed Web of Science ®Google Scholar
• Pan S, Zhan Y, Chen X, Wu B, Liu B. Bladder cancer exhibiting high immune infiltration shows the lowest response rate to immune checkpoint inhibitors. Front Oncol. 2019;9:1101. doi:10.3389/fonc.2019.01101.
   PubMed Web of Science ®Google Scholar
• Tang L, Huang ZP, Mei H, Hu Y. Insights gained from single-cell analysis of chimeric antigen receptor T-cell immunotherapy in cancer. Mil Med Res. 2023;10(1):52. doi:10.1186/s40779-023-00486-4.
   PubMed Web of Science ®Google Scholar
• Spassova I, Ugurel S, Terheyden P, Sucker A, Hassel JC, Ritter C, Kubat L, Habermann D, Farahpour F, Saeedghalati M, et al. Predominance of central memory T cells with high T-Cell receptor repertoire diversity is associated with response to PD-1/PD-L1 inhibition in Merkel cell carcinoma. Clin Cancer Res. 2020;26(9):2257–67. doi:10.1158/1078-0432.CCR-19-2244.
   PubMed Web of Science ®Google Scholar
• Arina A, Beckett M, Fernandez C, Zheng W, Pitroda S, Chmura SJ, Luke JJ, Forde M, Hou Y, Burnette B, et al. Tumor-reprogrammed resident T cells resist radiation to control tumors. Nat Commun. 2019;10(1):3959. doi:10.1038/s41467-019-11906-2.
   PubMedGoogle Scholar
• Chen JL, Pan CK, Huang YS, Tsai CY, Wang CW, Lin YL, Kuo SH, Shieh MJ. Evaluation of antitumor immunity by a combination treatment of high-dose irradiation, anti-PDL1, and anti-angiogenic therapy in murine lung tumors. Cancer Immunol Immunother. 2021;70(2):391–404. doi:10.1007/s00262-020-02690-w.
   PubMed Web of Science ®Google Scholar
• Losurdo A, Scirgolea C, Alvisi G, Brummelman J, Errico V, Di Tommaso L, Pilipow K, Colombo FS, Fernandes B, Peano C, et al. Single-cell profiling defines the prognostic benefit of CD39(high) tissue resident memory CD8+ T cells in luminal-like breast cancer. Commun Biol. 2021;4(1):1117. doi:10.1038/s42003-021-02595-z.
   PubMed Web of Science ®Google Scholar
• Lin L, Kane N, Kobayashi N, Kono EA, Yamashiro JM, Nickols NG, Reiter RE. High-dose per fraction radiotherapy induces both antitumor immunity and immunosuppressive responses in prostate tumors. Clin Cancer Res. 2021;27(5):1505–15. doi:10.1158/1078-0432.CCR-20-2293.
   PubMed Web of Science ®Google Scholar
• Dovedi SJ, Adlard AL, Lipowska-Bhalla G, McKenna C, Jones S, Cheadle EJ, Stratford IJ, Poon E, Morrow M, Stewart R, et al. Acquired resistance to fractionated radiotherapy can be overcome by concurrent PD-L1 blockade. Cancer Res. 2014;74(19):5458. doi:10.1158/0008-5472.CAN-14-1258.
   PubMed Web of Science ®Google Scholar
• Graham CH, Pare JF, Cotechini T, Hopman W, Hindmarch CCT, Ghaffari A, Marginean D, Chenard S, Koti M, Siemens DR. Innate immune memory is associated with increased disease-free survival in bladder cancer patients treated with bacillus Calmette-Guerin. Can Urol Assoc J. 2021;15(8):E412–17. doi:10.5489/cuaj.7066.
   PubMed Web of Science ®Google Scholar
• Netea MG, Joosten LA, Latz E, Mills KH, Natoli G, Stunnenberg HG, O’Neill LA, Xavier RJ. Trained immunity: a program of innate immune memory in health and disease. Science. 2016;352(6284):aaf1098. doi:10.1126/science.aaf1098.
   PubMed Web of Science ®Google Scholar
• Canale FP, Neumann J, von Renesse J. Proteomics of immune cells from liver tumors reveals immunotherapy targets. Cell Gemomics. 2023;3(6):100331. doi:10.1016/j.xgen.2023.100331.
   Google Scholar
• Song Q, Yang Y, Jiang D, Qin Z, Xu C, Wang H, Huang J, Chen L, Luo R, Zhang X, et al. Proteomic analysis reveals key differences between squamous cell carcinomas and adenocarcinomas across multiple tissues. Nat Commun. 2022;13(1):4167. doi:10.1038/s41467-022-31719-0.
   PubMed Web of Science ®Google Scholar
• Groeneveld CS, Sanchez-Quiles V, Dufour F, Shi M, Dingli F, Nicolle R, Chapeaublanc E, Poullet P, Jeffery D, Krucker C, et al. Proteogenomic characterization of bladder cancer reveals sensitivity to apoptosis induced by tumor necrosis factor–related apoptosis-inducing ligand in FGFR3-mutated tumors. Eur Urol. 2024;85(5):483–94. doi:10.1016/j.eururo.2023.05.037.
   PubMed Web of Science ®Google Scholar
• Shinde-Jadhav S, Mansure JJ, Rayes RF, Marcq G, Ayoub M, Skowronski R, Kool R, Bourdeau F, Brimo F, Spicer J, et al. Role of neutrophil extracellular traps in radiation resistance of invasive bladder cancer. Nat Commun. 2021;12(1):2776. doi:10.1038/s41467-021-23086-z.
   PubMed Web of Science ®Google Scholar
• Ayoub M, Shinde-Jadhav S, Mansure JJ, Alvarez F, Connell T, Seuntjens J, Piccirillo CA, Kassouf W. The immune mediated role of extracellular HMGB1 in a heterotopic model of bladder cancer radioresistance. Sci Rep. 2019;9(1):6348. doi:10.1038/s41598-019-42864-w.
   PubMedGoogle Scholar